APA (7th ed.) Citation

Elrosasy, A., Sabbagh, D., Assaf, M., Tarakhan, H., Afyouni, A., Elgendy, M. O., . . . Zabady, A. H. (2024). Efficacy and safety of ziltivekimab in patients with chronic kidney disease susceptible to inflammatory diseases: A systematic review and meta-analysis of randomized controlled trials. Future Journal of Pharmaceutical Sciences, 10(1), 1. https://doi.org/10.1186/s43094-024-00723-0

Chicago Style (17th ed.) Citation

Elrosasy, Amr, Dalal Sabbagh, Mohammad Assaf, Husam Tarakhan, Ahmad Afyouni, Marwa O. Elgendy, Lamiaa N. Abdelaty, Refaat H. Omar, and Ahmed Hamdy Zabady. "Efficacy and Safety of Ziltivekimab in Patients with Chronic Kidney Disease Susceptible to Inflammatory Diseases: A Systematic Review and Meta-analysis of Randomized Controlled Trials." Future Journal of Pharmaceutical Sciences 10, no. 1 (2024): 1. https://doi.org/10.1186/s43094-024-00723-0.

MLA (9th ed.) Citation

Elrosasy, Amr, et al. "Efficacy and Safety of Ziltivekimab in Patients with Chronic Kidney Disease Susceptible to Inflammatory Diseases: A Systematic Review and Meta-analysis of Randomized Controlled Trials." Future Journal of Pharmaceutical Sciences, vol. 10, no. 1, 2024, p. 1, https://doi.org/10.1186/s43094-024-00723-0.